Filing Flows › Comparisons › ABT vs GSK
Abbott Laboratories vs GSK: ABT and GSK compared
Abbott Laboratories is the larger company: $13.0B of revenue in its latest quarter (Q3 2026) against $8.5B for GSK (Q3 2026). GSK is more profitable, with an operating margin of 30.3% against 10.4%.
Where the money goes: ABT and GSK
Abbott Laboratories (ABT) · Q3 2026
Abbott Laboratories, Q3 2026: revenue $13.0B (+14% year over year), operating margin 10.4%, net earnings $920M, operating cash flow $1.7B. The chart follows the revenue to costs, profit and cash.
GSK (GSK) · Q3 2026
GSK, Q3 2026: revenue $8.5B, operating margin 30.3%, net earnings $2.0B. The chart follows the revenue to costs, profit and cash.
| Abbott Laboratories (ABT) | GSK (GSK) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $13.0B | $8.5B |
| Revenue growth, Y/Y | +14% | — |
| Gross margin | — | 73.6% |
| Operating margin | 10.4% | 30.3% |
| Net earnings | $920M | $2.0B |
| Net margin | 7.1% | 23.6% |
| Operating cash flow | $1.7B | — |
| Free cash flow | $1.2B | — |
| Market value | $197.4B | — |
| P/E | 42.4× | — |
| Analysts’ mean target | $118.52 | — |
Where the revenue comes from
GSK
- Specialty Medicines: $3.9B (45%)
- Dolutegravir products: $1.4B (17%)
- Dovato: $754M (9%)
- Long Acting Injectables: $621M (7%)
Questions
Which is bigger, Abbott Laboratories or GSK?
Abbott Laboratories is the larger company: $13.0B of revenue in its latest quarter (Q3 2026) against $8.5B for GSK (Q3 2026).
Is Abbott Laboratories or GSK growing faster?
GSK is more profitable, with an operating margin of 30.3% against 10.4%.
More: Abbott Laboratories earnings · how Abbott Laboratories makes money · GSK earnings · how GSK makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 6-K filed Oct 28, 2026). Fiscal quarters can end on different dates. Not investment advice.